Belumosudil mesylate Oral Suspension(Sanofi)
甲磺酸贝舒地尔口服混悬剂（赛诺菲）
Report date: 2025/10/22 15:18:28
Base Information
Drug NameBelumosudil mesylate Oral Suspension(Sanofi)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSanofi-Aventis Recherche & Developpement
China Registration ClassN/A
Develop Information
Active CompaniesSanofi-Aventis Recherche & Developpement
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A